Article info

Download PDFPDF

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Authors

  1. a 216-445-6592 OrnsteM{at}ccf.org
  2. b WoodL{at}ccf.org
  3. c HobbsB{at}ccf.org
  4. d AllmanK{at}ccf.org
  5. e MartinA2{at}ccf.org
  6. f BevanM{at}ccf.org
  7. g GilligT{at}ccf.org
  8. h GarciaJ4{at}ccf.org
  9. i RiniB2{at}ccf.org
View Full Text

Citation

Ornstein MC, Wood LS, Hobbs BP, et al
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Publication history

  • Received February 11, 2019
  • Accepted May 8, 2019
  • First published May 16, 2019.
Online issue publication 
May 16, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.